Does the media prefer UTHR or MRNA?

In the previous week, Moderna had 46 more articles in the media than United Therapeutics. MarketBeat recorded 60 mentions for Moderna and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Moderna's score of 0.21 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 15 Very Positive mention(s) 15 Positive mention(s) 16 Neutral mention(s) 5 Negative mention(s) 7 Very Negative mention(s) Neutral

Does the media favor UTHR or REGN?

In the previous week, Regeneron Pharmaceuticals had 9 more articles in the media than United Therapeutics. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Regeneron Pharmaceuticals' score of 0.55 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Regeneron Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor NTRA or UTHR?

In the previous week, Natera had 6 more articles in the media than United Therapeutics. MarketBeat recorded 20 mentions for Natera and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Natera's score of 0.31 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Natera 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARGX or UTHR?

In the previous week, argenex had 17 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for argenex and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat argenex's score of 0.16 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer UTHR or RVMD?

In the previous week, United Therapeutics had 6 more articles in the media than Revolution Medicines. MarketBeat recorded 14 mentions for United Therapeutics and 8 mentions for Revolution Medicines. United Therapeutics' average media sentiment score of 0.74 beat Revolution Medicines' score of 0.35 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

United Therapeutics (UTHR) Competitors

$545.66 -4.44 (-0.81%)

As of 11:25 AM Eastern

Compare

UTHR vs. MRNA, REGN, NTRA, ARGX, and RVMD

Should you buy United Therapeutics stock or one of its competitors? United Therapeutics's main competitors and comparable companies include Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Natera (NTRA), argenex (ARGX), and Revolution Medicines (RVMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does United Therapeutics compare to Moderna?

United Therapeutics (NASDAQ:UTHR) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

United Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

United Therapeutics presently has a consensus price target of $627.31, suggesting a potential upside of 14.04%. Moderna has a consensus price target of $78.17, suggesting a potential downside of 63.43%. Given United Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe United Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

United Therapeutics has a net margin of 41.56% compared to Moderna's net margin of -141.43%. United Therapeutics' return on equity of 20.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Moderna	-141.43%	-28.30%	-19.39%

United Therapeutics has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68
Moderna	$1.94B	43.90	-$2.82B	-$7.99	N/A

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Moderna had 46 more articles in the media than United Therapeutics. MarketBeat recorded 60 mentions for Moderna and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Moderna's score of 0.21 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	15 Very Positive mention(s)	15 Positive mention(s)	16 Neutral mention(s)	5 Negative mention(s)	7 Very Negative mention(s)	Neutral

Summary

United Therapeutics beats Moderna on 12 of the 16 factors compared between the two stocks.

How does United Therapeutics compare to Regeneron Pharmaceuticals?

United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

United Therapeutics has a net margin of 41.56% compared to Regeneron Pharmaceuticals' net margin of 27.86%. United Therapeutics' return on equity of 20.18% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68
Regeneron Pharmaceuticals	$15.53B	5.06	$4.50B	$40.46	18.85

United Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

In the previous week, Regeneron Pharmaceuticals had 9 more articles in the media than United Therapeutics. MarketBeat recorded 23 mentions for Regeneron Pharmaceuticals and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Regeneron Pharmaceuticals' score of 0.55 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

United Therapeutics currently has a consensus target price of $627.31, suggesting a potential upside of 14.04%. Regeneron Pharmaceuticals has a consensus target price of $834.24, suggesting a potential upside of 9.36%. Given United Therapeutics' higher possible upside, equities analysts clearly believe United Therapeutics is more favorable than Regeneron Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Regeneron Pharmaceuticals	0 Sell rating(s)	9 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.74

Summary

United Therapeutics beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Natera?

Natera (NASDAQ:NTRA) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Natera presently has a consensus price target of $357.26, suggesting a potential downside of 10.18%. United Therapeutics has a consensus price target of $627.31, suggesting a potential upside of 14.04%. Given United Therapeutics' higher probable upside, analysts plainly believe United Therapeutics is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natera	1 Sell rating(s)	4 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.83
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

99.9% of Natera shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Natera had 6 more articles in the media than United Therapeutics. MarketBeat recorded 20 mentions for Natera and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat Natera's score of 0.31 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Natera	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natera	$2.31B	24.86	-$208.16M	-$1.36	N/A
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68

Natera has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

United Therapeutics has a net margin of 41.56% compared to Natera's net margin of -7.11%. United Therapeutics' return on equity of 20.18% beat Natera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Natera	-7.11%	-11.38%	-7.87%
United Therapeutics	41.56%	20.18%	17.98%

Summary

United Therapeutics beats Natera on 10 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to argenex?

argenex (NASDAQ:ARGX) and United Therapeutics (NASDAQ:UTHR) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

argenex currently has a consensus target price of $1,155.05, suggesting a potential upside of 42.20%. United Therapeutics has a consensus target price of $627.31, suggesting a potential upside of 14.04%. Given argenex's stronger consensus rating and higher probable upside, equities research analysts clearly believe argenex is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.83
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

United Therapeutics has a net margin of 41.56% compared to argenex's net margin of 32.19%. argenex's return on equity of 43.59% beat United Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	32.19%	43.59%	36.66%
United Therapeutics	41.56%	20.18%	17.98%

60.3% of argenex shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

United Therapeutics has lower revenue, but higher earnings than argenex. United Therapeutics is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.96	$1.29B	$26.04	31.19
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68

argenex has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, argenex had 17 more articles in the media than United Therapeutics. MarketBeat recorded 31 mentions for argenex and 14 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.74 beat argenex's score of 0.16 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats United Therapeutics on 10 of the 17 factors compared between the two stocks.

How does United Therapeutics compare to Revolution Medicines?

United Therapeutics (NASDAQ:UTHR) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

United Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market.

United Therapeutics has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	7.41	$1.33B	$27.95	19.68
Revolution Medicines	$11.58M	3,589.92	-$1.13B	-$8.82	N/A

In the previous week, United Therapeutics had 6 more articles in the media than Revolution Medicines. MarketBeat recorded 14 mentions for United Therapeutics and 8 mentions for Revolution Medicines. United Therapeutics' average media sentiment score of 0.74 beat Revolution Medicines' score of 0.35 indicating that United Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

United Therapeutics has a net margin of 41.56% compared to Revolution Medicines' net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
Revolution Medicines	N/A	-88.20%	-57.85%

United Therapeutics presently has a consensus price target of $627.31, indicating a potential upside of 14.04%. Revolution Medicines has a consensus price target of $234.76, indicating a potential upside of 21.04%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

United Therapeutics beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UTHR vs. The Competition

Export

Metric	United Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$23.33B	$3.87B	$7.20B	$13.20B
Dividend Yield	N/A	3.65%	2.52%	20.73%
P/E Ratio	19.47	13.36	275.27	25.83
Price / Sales	7.33	1,197.26	621.35	102.96
Price / Cash	16.65	39.46	27.30	36.12
Price / Book	3.30	16.73	10.58	6.05
Net Income	$1.33B	-$22.69M	$3.49B	$380.34M
7 Day Performance	0.43%	-2.90%	-2.10%	-2.37%
1 Month Performance	9.42%	-10.52%	-5.65%	-4.56%
1 Year Performance	23.61%	11.35%	4.88%	-2.00%

United Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UTHR United Therapeutics	3.9006 of 5 stars	$545.66 -0.8%	$627.31 +15.0%	+25.0%	$23.40B	$3.18B	19.52	1,400
MRNA Moderna	1.7715 of 5 stars	$203.21 +6.9%	$77.83 -61.7%	+696.6%	$75.86B	$1.94B	N/A	4,700	Trending News Gap Down
REGN Regeneron Pharmaceuticals	4.582 of 5 stars	$726.47 -1.2%	$809.50 +11.4%	+35.1%	$75.69B	$14.34B	17.96	15,410
NTRA Natera	1.8847 of 5 stars	$425.64 +3.7%	$341.55 -19.8%	+135.0%	$59.15B	$2.31B	N/A	6,140	Analyst Forecast
ARGX argenex	4.6608 of 5 stars	$912.87 -0.7%	$1,158.61 +26.9%	+1.9%	$57.51B	$5.23B	35.06	1,863	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UTHR) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

United Therapeutics (UTHR) Competitors

UTHR vs. MRNA, REGN, NTRA, ARGX, and RVMD

How does United Therapeutics compare to Moderna?

Summary

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Summary

How does United Therapeutics compare to Natera?

Summary

How does United Therapeutics compare to argenex?

Summary

How does United Therapeutics compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

United Therapeutics (UTHR) Competitors

UTHR vs. MRNA, REGN, NTRA, ARGX, and RVMD

How does United Therapeutics compare to Moderna?

Which has more volatility & risk, UTHR or MRNA?

Do analysts rate UTHR or MRNA?

Is UTHR or MRNA more profitable?

Which has stronger valuation & earnings, UTHR or MRNA?

Do institutionals & insiders hold more shares of UTHR or MRNA?

Does the media prefer UTHR or MRNA?

Summary

How does United Therapeutics compare to Regeneron Pharmaceuticals?

Do institutionals and insiders hold more shares of UTHR or REGN?

Is UTHR or REGN more profitable?

Which has higher earnings & valuation, UTHR or REGN?

Which has more risk & volatility, UTHR or REGN?

Does the media favor UTHR or REGN?

Do analysts prefer UTHR or REGN?

Summary

How does United Therapeutics compare to Natera?

Do analysts prefer NTRA or UTHR?

Do insiders and institutionals hold more shares of NTRA or UTHR?

Does the media favor NTRA or UTHR?

Which has preferable earnings and valuation, NTRA or UTHR?

Which has more risk and volatility, NTRA or UTHR?

Is NTRA or UTHR more profitable?

Summary

How does United Therapeutics compare to argenex?

Do analysts prefer ARGX or UTHR?

Is ARGX or UTHR more profitable?

Do insiders & institutionals hold more shares of ARGX or UTHR?

Which has better valuation and earnings, ARGX or UTHR?

Which has more volatility and risk, ARGX or UTHR?

Does the media favor ARGX or UTHR?

Summary

How does United Therapeutics compare to Revolution Medicines?

Which has more risk & volatility, UTHR or RVMD?

Which has preferable valuation & earnings, UTHR or RVMD?

Does the media prefer UTHR or RVMD?

Do institutionals and insiders believe in UTHR or RVMD?

Is UTHR or RVMD more profitable?

Do analysts prefer UTHR or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UTHR vs. The Competition

United Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools